Literature DB >> 21896490

Ubiquitin-mediated regulation of CD86 protein expression by the ubiquitin ligase membrane-associated RING-CH-1 (MARCH1).

Kathleen Corcoran1, Maurice Jabbour, Candida Bhagwandin, Martin J Deymier, Debra L Theisen, Lonnie Lybarger.   

Abstract

The activation of naïve T cells requires antigen presentation by dendritic cells (DCs), and the process of antigen presentation is regulated over the course of DC maturation. One key aspect of this regulation is the cell surface up-regulation upon DC maturation of peptide·MHC-II complexes and the costimulatory molecule CD86. It is now clear that these critical induction events involve changes in ubiquitin-dependent trafficking of MHC-II and CD86 by the E3 ligase membrane-associated RING-CH-1 (MARCH1). Although ubiquitin-dependent trafficking of MHC-II has been well characterized, much less is known regarding the post-transcriptional regulation of CD86 expression. Here, we examined the physical and functional interaction between CD86 and MARCH1. We observed that CD86 is rapidly endocytosed in the presence of MARCH1 followed by lysosome-dependent degradation. Furthermore, we found that the association between CD86 and MARCH1 was conferred primarily by the transmembrane domains of the respective proteins. In contrast to MHC-II, which has a single, conserved ubiquitin acceptor site in the cytosolic domain, we found that multiple lysine residues in the cytosolic tail of CD86 could support ubiquitination consistent with the relative lack of sequence conservation across species within the CD86 cytosolic domain. These findings suggest that MARCH1 recruits multiple substrates via transmembrane domain-mediated interactions to permit substrate ubiquitination in the face of diverse cytosolic domain sequences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896490      PMCID: PMC3199464          DOI: 10.1074/jbc.M110.204040

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation.

Authors:  L Coscoy; D Ganem
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Functional organization of MIR2, a novel viral regulator of selective endocytosis.

Authors:  David Jesse Sanchez; Laurent Coscoy; Don Ganem
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

3.  MHC class II expression is regulated in dendritic cells independently of invariant chain degradation.

Authors:  J A Villadangos; M Cardoso; R J Steptoe; D van Berkel; J Pooley; F R Carbone; K Shortman
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

4.  Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation.

Authors:  Eric W Hewitt; Lidia Duncan; Dina Mufti; John Baker; Philip G Stevenson; Paul J Lehner
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

Review 5.  PHD domains and E3 ubiquitin ligases: viruses make the connection.

Authors:  Laurent Coscoy; Don Ganem
Journal:  Trends Cell Biol       Date:  2003-01       Impact factor: 20.808

6.  Virus subversion of the MHC class I peptide-loading complex.

Authors:  Lonnie Lybarger; Xiaoli Wang; Michael R Harris; Herbert W Virgin; Ted H Hansen
Journal:  Immunity       Date:  2003-01       Impact factor: 31.745

7.  Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells.

Authors:  Louise J Young; Nicholas S Wilson; Petra Schnorrer; Anna Proietto; Toine ten Broeke; Yohei Matsuki; Adele M Mount; Gabrielle T Belz; Meredith O'Keeffe; Mari Ohmura-Hoshino; Satoshi Ishido; Willem Stoorvogel; William R Heath; Ken Shortman; Jose A Villadangos
Journal:  Nat Immunol       Date:  2008-10-12       Impact factor: 25.606

8.  c-MIR, a human E3 ubiquitin ligase, is a functional homolog of herpesvirus proteins MIR1 and MIR2 and has similar activity.

Authors:  Eiji Goto; Satoshi Ishido; Yuya Sato; Shinji Ohgimoto; Kaori Ohgimoto; Motoko Nagano-Fujii; Hak Hotta
Journal:  J Biol Chem       Date:  2003-02-11       Impact factor: 5.157

9.  MHC class I ubiquitination by a viral PHD/LAP finger protein.

Authors:  J M Boname; P G Stevenson
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

10.  Interleukin-10-induced MARCH1 mediates intracellular sequestration of MHC class II in monocytes.

Authors:  Jacques Thibodeau; Marie-Claude Bourgeois-Daigneault; Gabrielle Huppé; Jessy Tremblay; Angélique Aumont; Mathieu Houde; Eric Bartee; Alexandre Brunet; Marie-Elaine Gauvreau; Aude de Gassart; Evelina Gatti; Martin Baril; Maryse Cloutier; Séverine Bontron; Klaus Früh; Daniel Lamarre; Viktor Steimle
Journal:  Eur J Immunol       Date:  2008-05       Impact factor: 5.532

View more
  33 in total

Review 1.  The ins and outs of MHC class II-mediated antigen processing and presentation.

Authors:  Paul A Roche; Kazuyuki Furuta
Journal:  Nat Rev Immunol       Date:  2015-02-27       Impact factor: 53.106

2.  The E3 ubiquitin ligase MARCH1 regulates antimalaria immunity through interferon signaling and T cell activation.

Authors:  Jian Wu; Lu Xia; Xiangyu Yao; Xiao Yu; Keyla C Tumas; Wenxiang Sun; Yang Cheng; Xiao He; Yu-Chih Peng; Brajesh K Singh; Cui Zhang; Chen-Feng Qi; Silvia Bolland; Sonja M Best; Channe Gowda; Ruili Huang; Timothy G Myers; Carole A Long; Rong-Fu Wang; Xin-Zhuan Su
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-30       Impact factor: 11.205

Review 3.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

4.  A serine in the first transmembrane domain of the human E3 ubiquitin ligase MARCH9 is critical for down-regulation of its protein substrates.

Authors:  Cyrus Tan; Eamon F X Byrne; Casey Ah-Cann; Melissa J Call; Matthew E Call
Journal:  J Biol Chem       Date:  2018-12-15       Impact factor: 5.157

5.  Membrane-associated RING-CH (MARCH) 1 and 2 are MARCH family members that inhibit HIV-1 infection.

Authors:  Yanzhao Zhang; Takuya Tada; Seiya Ozono; Weitong Yao; Michiko Tanaka; Shoji Yamaoka; Satoshi Kishigami; Hideaki Fujita; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2019-01-10       Impact factor: 5.157

6.  Tollip-induced down-regulation of MARCH1.

Authors:  Marie-Claude Bourgeois-Daigneault; Abdul Mohammad Pezeshki; Tristan Galbas; Mathieu Houde; Martin Baril; Klaus Früh; Abdelaziz Amrani; Satoshi Ishido; Daniel Lamarre; Jacques Thibodeau
Journal:  Results Immunol       Date:  2013-02-20

7.  A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model.

Authors:  Isaac M Chiu; Emiko T A Morimoto; Hani Goodarzi; Jennifer T Liao; Sean O'Keeffe; Hemali P Phatnani; Michael Muratet; Michael C Carroll; Shawn Levy; Saeed Tavazoie; Richard M Myers; Tom Maniatis
Journal:  Cell Rep       Date:  2013-07-11       Impact factor: 9.423

8.  Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes.

Authors:  Christopher R Lucas; Hector M Cordero-Nieves; Robert S Erbe; Jaclyn W McAlees; Sumeena Bhatia; Richard J Hodes; Kerry S Campbell; Virginia M Sanders
Journal:  J Immunol       Date:  2012-12-12       Impact factor: 5.422

9.  Interleukin 10 (IL-10)-mediated Immunosuppression: MARCH-I INDUCTION REGULATES ANTIGEN PRESENTATION BY MACROPHAGES BUT NOT DENDRITIC CELLS.

Authors:  Sharad K Mittal; Kyung-Jin Cho; Satoshi Ishido; Paul A Roche
Journal:  J Biol Chem       Date:  2015-09-25       Impact factor: 5.157

10.  Suppression by Δ(9)-tetrahydrocannabinol of the primary immunoglobulin M response by human peripheral blood B cells is associated with impaired STAT3 activation.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Stephen Carney; Robert Crawford; Norbert E Kaminski
Journal:  Toxicology       Date:  2013-05-29       Impact factor: 4.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.